Evidence map›Paper›PMID 42380934›Full record

ArticleBMC research notes2026

Phenotypical and functional characterization of a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9.

Sarah Kammerer, Natalie Herzog, Thea Jenchen, Valentina Stock, Rebecca Hofer, Veronika Ruzsanyi, Jan-Heiner Küpper

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah KammererInstitute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany. sarah.kammerer@b-tu.de.ORCID https://orcid.org/0000-0002-9284-2242
Natalie HerzogInstitute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany.
Thea JenchenInstitute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany.
Valentina StockInstitute for Breath Research, Universität Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.
Rebecca HoferInstitute for Breath Research, Universität Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.
Veronika RuzsanyiInstitute for Breath Research, Universität Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.
Jan-Heiner KüpperInstitute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968, Senftenberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to generate a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9 together with an empty vector (EV) control cell clone for pharmacological and toxicological studies of substances with CYP2C9-mediated biotransformation.

resultsA new HepG2 cell clone was generated by lentiviral transduction to functionally overexpress human CYP2C9. We found high CYP2C9 transcript and protein levels based on qRT-PCR, Western blot and immunofluorescence in the cell clone. Most importantly, specific enzyme activities of 62.9 ± 2.6 pmol 4-hydroxydiclofenac/min/10

Indexed as

Cytochrome P-450 CYP2C9Clone CellsCytochrome P-450 CYP2C9 InhibitorsDiclofenacHep G2 CellsHumansLentivirusPhenotypeSulfaphenazoleCYP2C9 protein, humanCytochrome P-450 CYP2C9Cytochrome P-450 CYP2C9 InhibitorsDiclofenacSulfaphenazoleCYP2C9Cytochrome P450Enzyme activityHepG2Lentiviral transductionOverexpressing cell line

Identifiers

PMID42380934
PMCPMC13321531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.